C

CytomX Therapeutics
D

CTMX

0.83110
USD
-0.03
(-3.53%)
مغلق
حجم التداول
4,276
الربح لكل سهم
-0
العائد الربحي
-
P/E
5
حجم السوق
65,040,954
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    AMGN
    AMGN
    -1.26
    (-0.46%)
    273.59 USD
    BIIB
    BIIB
    1.810
    (1.28%)
    142.750 USD
    BMY
    BMY
    0.025
    (0.04%)
    57.075 USD
    GILD
    GILD
    0.070
    (0.08%)
    93.020 USD
    LLY
    LLY
    11.37
    (1.53%)
    753.86 USD
    MRK
    MRK
    -0.560
    (-0.58%)
    95.670 USD
    PFE
    PFE
    -0.621
    (-2.33%)
    26.015 USD
    REGN
    REGN
    -7.47
    (-1.09%)
    679.85 USD
    VRTX
    VRTX
    0.08
    (0.02%)
    428.09 USD
    المزيد
الأخبار
المقالات

العنوان: CytomX Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.